190 related articles for article (PubMed ID: 38673021)
1. BAP1 Loss, Nuclear Grading, and Nonepithelioid Features in the Diagnosis of Mesothelioma in Italy: Nevermore without the Pathology Report.
Rossi G; Righi L; Barbisan F; Tiseo M; Spagnolo P; Grosso F; Pisapia P; Malapelle U; Sculco M; Dianzani I; Abate-Daga L; Davolio MC; Ceresoli GL; Galetta D; Pasello G; Novello S; Bironzo P
J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673021
[TBL] [Abstract][Full Text] [Related]
2. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
3. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
4. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
[TBL] [Abstract][Full Text] [Related]
5. The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification.
Sauter JL; Dacic S; Galateau-Salle F; Attanoos RL; Butnor KJ; Churg A; Husain AN; Kadota K; Khoor A; Nicholson AG; Roggli V; Schmitt F; Tsao MS; Travis WD
J Thorac Oncol; 2022 May; 17(5):608-622. PubMed ID: 35026477
[TBL] [Abstract][Full Text] [Related]
6. A Critical Assessment of Current Grading Schemes for Diffuse Pleural Mesothelioma With a Proposal for a Novel Mesothelioma Weighted Grading Scheme (MWGS).
Fuchs TL; Chou A; Aksoy Y; Mahjoub M; Sheen A; Sioson L; Ahadi M; Gill AJ
Am J Surg Pathol; 2022 Jun; 46(6):774-785. PubMed ID: 34907994
[TBL] [Abstract][Full Text] [Related]
7. The 2015 World Health Organization Classification of Tumors of the Pleura: Advances since the 2004 Classification.
Galateau-Salle F; Churg A; Roggli V; Travis WD;
J Thorac Oncol; 2016 Feb; 11(2):142-54. PubMed ID: 26811225
[TBL] [Abstract][Full Text] [Related]
8. New Insights in Pleural Mesothelioma Classification Update: Diagnostic Traps and Prognostic Implications.
Mastromarino MG; Lenzini A; Aprile V; Alì G; Bacchin D; Korasidis S; Ambrogi MC; Lucchi M
Diagnostics (Basel); 2022 Nov; 12(12):. PubMed ID: 36552912
[TBL] [Abstract][Full Text] [Related]
9. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
10. Characterizing the distribution of alterations in mesothelioma and their correlation to morphology.
Chen-Yost HI; Tjota MY; Gao G; Mitchell O; Kindler H; Segal J; Husain AN; Mueller J; Schulte JJ
Am J Clin Pathol; 2023 Sep; 160(3):238-246. PubMed ID: 37141416
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemistry for Claudin-4 and BAP1 in the Differential Diagnosis between Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Zuccatosta L; Bizzarro T; Rossi G; Gallo G; Gasparini S; Ambrosini-Spaltro A
Diagnostics (Basel); 2023 Jan; 13(2):. PubMed ID: 36673059
[TBL] [Abstract][Full Text] [Related]
12. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
Nicholson AG; Sauter JL; Nowak AK; Kindler HL; Gill RR; Remy-Jardin M; Armato SG; Fernandez-Cuesta L; Bueno R; Alcala N; Foll M; Pass H; Attanoos R; Baas P; Beasley MB; Brcic L; Butnor KJ; Chirieac LR; Churg A; Courtiol P; Dacic S; De Perrot M; Frauenfelder T; Gibbs A; Hirsch FR; Hiroshima K; Husain A; Klebe S; Lantuejoul S; Moreira A; Opitz I; Perol M; Roden A; Roggli V; Scherpereel A; Tirode F; Tazelaar H; Travis WD; Tsao MS; van Schil P; Vignaud JM; Weynand B; Lang-Lazdunski L; Cree I; Rusch VW; Girard N; Galateau-Salle F
J Thorac Oncol; 2020 Jan; 15(1):29-49. PubMed ID: 31546041
[TBL] [Abstract][Full Text] [Related]
13. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma.
De Rienzo A; Chirieac LR; Hung YP; Severson DT; Freyaldenhoven S; Gustafson CE; Dao NT; Meyerovitz CV; Oster ME; Jensen RV; Yeap BY; Bueno R; Richards WG
J Pathol; 2021 Jan; 253(1):68-79. PubMed ID: 32944962
[TBL] [Abstract][Full Text] [Related]
14. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations.
Cigognetti M; Lonardi S; Fisogni S; Balzarini P; Pellegrini V; Tironi A; Bercich L; Bugatti M; Rossi G; Murer B; Barbareschi M; Giuliani S; Cavazza A; Marchetti G; Vermi W; Facchetti F
Mod Pathol; 2015 Aug; 28(8):1043-57. PubMed ID: 26022455
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of prognostic histological parameters proposed for pleural mesothelioma in diffuse malignant peritoneal mesothelioma. A short report.
Pezzuto F; Vimercati L; Fortarezza F; Marzullo A; Pennella A; Cavone D; Punzi A; Caporusso C; d'Amati A; Lettini T; Serio G
Diagn Pathol; 2021 Jul; 16(1):64. PubMed ID: 34294087
[TBL] [Abstract][Full Text] [Related]
16. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
[TBL] [Abstract][Full Text] [Related]
17. Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Terra S; Roden AC; Yi ES; Aubry MC; Boland JM
Am J Clin Pathol; 2022 Jan; 157(1):33-39. PubMed ID: 34463336
[TBL] [Abstract][Full Text] [Related]
18. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
[TBL] [Abstract][Full Text] [Related]
19. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
